DE69919403D1 - Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen - Google Patents

Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen

Info

Publication number
DE69919403D1
DE69919403D1 DE69919403T DE69919403T DE69919403D1 DE 69919403 D1 DE69919403 D1 DE 69919403D1 DE 69919403 T DE69919403 T DE 69919403T DE 69919403 T DE69919403 T DE 69919403T DE 69919403 D1 DE69919403 D1 DE 69919403D1
Authority
DE
Germany
Prior art keywords
treatment
acid derivatives
nicotinic acid
dna damage
skin cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69919403T
Other languages
English (en)
Other versions
DE69919403T2 (de
Inventor
L Jacobson
K Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22333250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69919403(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Application granted granted Critical
Publication of DE69919403D1 publication Critical patent/DE69919403D1/de
Publication of DE69919403T2 publication Critical patent/DE69919403T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DE69919403T 1998-12-01 1999-12-01 Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen Expired - Lifetime DE69919403T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11048298P 1998-12-01 1998-12-01
US110482P 1998-12-01
PCT/US1999/028446 WO2000032179A2 (en) 1998-12-01 1999-12-01 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells

Publications (2)

Publication Number Publication Date
DE69919403D1 true DE69919403D1 (de) 2004-09-16
DE69919403T2 DE69919403T2 (de) 2005-09-08

Family

ID=22333250

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69919403T Expired - Lifetime DE69919403T2 (de) 1998-12-01 1999-12-01 Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen

Country Status (15)

Country Link
US (4) US6337065B1 (de)
EP (1) EP1143954B1 (de)
AR (1) AR023715A1 (de)
AT (1) ATE273008T1 (de)
AU (1) AU762770B2 (de)
CA (1) CA2352964C (de)
DE (1) DE69919403T2 (de)
DK (1) DK1143954T3 (de)
ES (1) ES2228146T3 (de)
HK (1) HK1041436B (de)
IL (2) IL143112A0 (de)
NZ (1) NZ511708A (de)
PT (1) PT1143954E (de)
TW (1) TWI257303B (de)
WO (1) WO2000032179A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337065B1 (en) * 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin
US20020054895A1 (en) 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US6864274B2 (en) 1999-07-23 2005-03-08 Alwyn Company, Inc. Allantoin-containing skin cream
US6896897B2 (en) 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
US6531500B2 (en) 1999-07-23 2003-03-11 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
US6673826B2 (en) 1999-07-23 2004-01-06 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
CN1318030C (zh) * 2000-04-14 2007-05-30 尼亚戴恩公司 用于增强向细胞释放氧的方法和组合物
DK1274429T3 (da) * 2000-04-14 2008-08-25 Niadyne Corp Topiske formuleringer til transdermal indgivelse af niacin-prolægemidler samt metoder til behandling af hyperlipidæmi
US20020182585A1 (en) * 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
CA2437844C (en) * 2001-03-08 2007-05-15 Elaine Jacobson Method for increasing leptin levels using nicotinic acid compounds
ITMI20011019A1 (it) * 2001-05-17 2002-11-17 Carlo Ghisalberti Sostanze furiliche per uso topico
AU2002950744A0 (en) * 2002-08-13 2002-09-12 Medihoney Pty Ltd Composition
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
WO2004056307A2 (en) * 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
CN101108001B (zh) * 2002-12-26 2011-12-14 味之素株式会社 保健功能食品
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
WO2004100990A1 (ja) 2003-05-19 2004-11-25 Genecare Research Institute Co., Ltd. 癌細胞に対するアポトーシス誘導剤
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7615641B2 (en) * 2004-07-20 2009-11-10 Sino Pharmaceuticals Corporation Long chain aliphatic alcohol derivatives and methods of making and using same
ES2646512T3 (es) 2005-06-24 2017-12-14 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Método para el tratamiento de trastornos del crecimiento del cabello, tales como la alopecia de patrón femenino, y composiciones útiles para el mismo
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008025755A1 (de) * 2006-09-01 2008-03-06 Basf Se Verwendung von n-haltigen heterozyklen in dermokosmetika
EP3231440A1 (de) * 2006-12-22 2017-10-18 CSL Behring GmbH Veränderte koagulationsfaktoren mit verlängerter in-vivo-halbwertzeit
PT2120917E (pt) * 2007-02-28 2014-04-24 Univ Kentucky Res Found Método para aliviar os efeitos secundários da terapia com ácido retinóico e/ou melhorar a sua eficácia sem interferir com a eficácia desse tratamento
AU2009221634B2 (en) * 2008-03-03 2014-05-08 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2168574A1 (de) 2008-09-25 2010-03-31 Noureddine Frid Verbindung zur lokalen Tumorentfernung
US8173446B2 (en) 2009-12-21 2012-05-08 General Electric Company Method of producing an integrated micromagnet sensor assembly
US20140135372A1 (en) 2010-02-02 2014-05-15 Elliott Farber Compositions and methods of treatment of inflammatory skin conditions using allantoin
US20140065099A1 (en) * 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
CN108026566A (zh) * 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
WO2020089236A1 (en) 2018-11-02 2020-05-07 Unilever Plc Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185679A (en) 1965-05-25 Azepine derivatives
US3276960A (en) 1961-08-21 1966-10-04 Kendall & Co Analgesic methods and compositions
US4246285A (en) 1975-10-20 1981-01-20 The Procter & Gamble Company Skin conditioning compositions containing guanidine inorganic salts
HU184626B (en) 1979-06-01 1984-09-28 Ferrokemia Ipari Congesting cosmetics first of all hair-restorers
DE3174885D1 (en) 1981-02-03 1986-07-31 Ici Plc Process for the extraction of metal values and novel metal extractants
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US5635497A (en) 1982-06-23 1997-06-03 Yamanouchi Europe B.V. Topical application compositions
US4459153A (en) 1982-09-20 1984-07-10 The United States Of America As Represented By The United States Department Of Energy Pyrochemical process for extracting plutonium from an electrolyte salt
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
DE3586859D1 (de) 1984-03-07 1993-01-07 Roshdy Ismail Mittel zur behandlung und zum schutz der haut.
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
EP0182635B1 (de) 1984-11-15 1989-05-31 Nitto Denko Corporation Zusammensetzung zur perkutanen Anwendung
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
DE3532562A1 (de) 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
LU86574A1 (fr) 1986-09-08 1988-04-05 Oreal Composition pour induire et stimuler la croissance des cheveux et freiner leur chute,a base d'esters nicotiniques et de derives de pyrimidine
GB2216003B (en) 1988-02-18 1992-06-10 Toyama Chemical Co Ltd Hair restorer
US4981681A (en) 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
US5133958A (en) 1989-04-20 1992-07-28 Erwin Stuckler Agent for nail, skin and hair care
US5129360A (en) 1990-01-24 1992-07-14 The United States Of America As Represented By The Secretary Of The Air Force Actively cooled effusion cell for chemical vapor deposition
GB9006785D0 (en) 1990-03-27 1990-05-23 Leung Lit Hung Composition and methods for treatment of acne vulgaris and retardation of ageing
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5043162A (en) 1990-09-05 1991-08-27 Trager Seymour F Hair growth promoter
FR2668366B1 (fr) * 1990-10-30 1993-01-29 Oreal Utilisation cosmetique d'une composition ayant une activite antierythemale et composition correspondante.
GB9114346D0 (en) 1991-07-03 1991-08-21 Dow Corning Sa A method of accelerating drug permeation
US5358969A (en) 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5240945A (en) 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US6231852B1 (en) * 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2715565B1 (fr) 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
DE69420746T2 (de) * 1994-06-02 2000-06-29 Dan Riga Arzneimittel gegen stress, beeinträchtigung und altwerden und verfahren zu ihrer herstellung
US5612382A (en) 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
DE4433130C2 (de) 1994-09-16 1997-02-06 Deutsches Krebsforsch Poly(ADP-Ribose)-Polymerase überexprimierende tierische Zellinien und Verfahren zur Identifizierung von DNA-schädigenden Substanzen
US5690944A (en) 1994-12-20 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing lactate dehydrogenase inhibitors
EP0717984B1 (de) 1994-12-20 2004-11-03 Unilever Plc Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln
WO1996028167A1 (en) * 1995-03-14 1996-09-19 Shaskan Edward G Compositions comprising nicotynylalanine and an inhibitor of glycine conjugation or vitamin b6
EP0823897B1 (de) 1995-05-01 2004-07-28 Scarista Limited Nicotinsäureester und diese enthaltende pharmazeutischen zusammensetzungen
JPH08301760A (ja) * 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
US5571794A (en) 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation
JP3542665B2 (ja) 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
JPH11511167A (ja) * 1995-08-14 1999-09-28 オキシジェン インコーポレイティド カロテノイド−ニコチンアミド−亜鉛組成物およびこれを使用した治療方法
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
AU711536B2 (en) * 1996-01-24 1999-10-14 Aliatros Medical A.S. Composition for treating cancer containing a ribose compound, beta-alanine, ascorbic acid and nicotinic acid
US5736529A (en) * 1996-03-22 1998-04-07 Neurocal International Inc. Use of NAD-related compounds in the treatment of neural trauma to inhibit neurodegeneration
AUPN892496A0 (en) * 1996-03-25 1996-04-18 Technical Consultancy Services Pty Limited Acne treatment
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
BR9908223A (pt) * 1998-03-16 2000-10-24 Procter & Gamble Método para reduzir celulite na pele de mamìferos
US6277613B1 (en) 1998-06-10 2001-08-21 The Rockefeller University TRF1 binding protein, methods of use thereof
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
US5976513A (en) 1998-10-16 1999-11-02 The Procter & Gamble Company UV protection compositions
US6337065B1 (en) * 1998-12-01 2002-01-08 University Of Kentucky Research Foundation Method for enhancing protective cellular responses to genotoxic stress in skin

Also Published As

Publication number Publication date
EP1143954B1 (de) 2004-08-11
DE69919403T2 (de) 2005-09-08
HK1041436A1 (en) 2002-07-12
US6552050B2 (en) 2003-04-22
WO2000032179A2 (en) 2000-06-08
US7425319B2 (en) 2008-09-16
TWI257303B (en) 2006-07-01
CA2352964A1 (en) 2000-06-08
AR023715A1 (es) 2002-09-04
AU762770B2 (en) 2003-07-03
IL143112A (en) 2006-10-31
PT1143954E (pt) 2004-12-31
IL143112A0 (en) 2002-04-21
HK1041436B (zh) 2005-03-11
AU1929200A (en) 2000-06-19
CA2352964C (en) 2006-10-17
US6403619B1 (en) 2002-06-11
EP1143954A2 (de) 2001-10-17
US20010033848A1 (en) 2001-10-25
NZ511708A (en) 2003-12-19
ES2228146T3 (es) 2005-04-01
US20040147491A1 (en) 2004-07-29
ATE273008T1 (de) 2004-08-15
DK1143954T3 (da) 2004-12-20
US6337065B1 (en) 2002-01-08
WO2000032179A3 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
DE69919403D1 (de) Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
ATE524173T1 (de) Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60023816D1 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE60139266D1 (de) Herstellungsverfahren und verwendung von tetrahydrocurcuminoiden zur regulierung der physiologischen und pathologischen fälle in der haut und in den schleimhautzellen
DE69719495D1 (de) Verwendung von inhibitoren der retinosäureaktivität zur behandlung empfindlicher haut und/oder durch uv strahlung bewirkter akuter schädigungen
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69940971D1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: WEICKMANN & WEICKMANN, 81679 MUENCHEN